The Michigan Medicine VAD Program is a regional and national referral center for patients and offers state-of-the-art options for mechanical circulatory support and skilled post-implantation care.

Our multidisciplinary team consists of cardiac surgeons, heart failure cardiologists, advanced practice professionals, biomedical engineers, research coordinators, a clinical information analyst, a clinical research coordinator, clinical care coordinators and a program manager. Our entire team strives to fulfill the Michigan Medicine VAD Program vision: To be the best and most comprehensive program for advanced technology of mechanical circulatory support therapy in the world.

Our VAD Program earned the Gold Seal of Approval® for health care quality on April 10, 2008, and was one of the first centers to be awarded Disease-Specific Care Certification for Ventricular Assist Devices by The Joint Commission. Recertification by The Joint Commission has been given every two years since 2010.

To earn this distinction, a disease management program undergoes an extensive on-site evaluation by a team of Joint Commission reviewers every two years. The program is evaluated against Joint Commission standards through an assessment of the program’s processes, the program’s ability to evaluate and improve care within its own organization, and interviews with patients and staff.

INVESTIGATIONAL AND FDA-APPROVED DEVICES
Our VAD Program is one of only a few worldwide that has access to many investigational and FDA-approved mechanical circulatory support systems including the HeartMate II® and HeartWare HVAD® left ventricular assist devices and SynCardia Total Artificial Heart. This allows for selection of the most appropriate device based on each patient’s individual needs.

Our physicians actively participate in several clinical trials evaluating new mechanical circulatory support devices in addition to developing new types of devices. To date the program has implanted more than 1,000 long-term devices and currently has over 190 patients on long-term VAD support.
OUR VAD TEAM

Advanced Heart Failure Cardiologist
Keith D. Aaronson, M.D.

VAD and Heart Transplant Surgeon
Francis D. Pagani, M.D., Ph.D.

Program Manager
Stacy Haverstick, M.H.A., R.N., P.C.C.N.-K.

Physician Assistants
Kevin Knott, P.A.-C.
Angela Rose, P.A.-C.

VAD Coordinators
Teresa Colaianne, B.S.N., R.N.
Rená Lucier, M.S.N., R.N.
Todd Saunders, B.S.N., R.N., C.C.R.N.
Linda Boland, B.S.N., R.N.

VAD Coordinator/Educational Nurse Coordinator
MJ Melong, B.S.N., R.N.

Equipment Specialists
Andy Griffith
Shawn Tuck

Clinical Info Analyst
Alondra Dorsey

Research Project Manager
Lydia McGowan, M.S., C.C.R.P.

Clinical Research Coordinator
Sheryl Korsnes, C.C.R.P.

Total Artificial Heart

Michigan Medicine cardiac surgeons have implanted 14 SynCardia total artificial hearts to date. The total artificial heart is often used when end-state heart failure affects both sides of the heart and other more common heart-supporting devices are inadequate to keep patients alive. A 14-pound Freedom Driver powers the total artificial heart with precisely calibrated pulses of air.

OUTREACH MANAGER, ERIKA LASZLO

For more information about how we care for patients with advanced heart failure or cardiogenic shock, or any other services offered at the Frankel Cardiovascular Center, please contact Erika Laszlo at elaszlo@med.umich.edu or via M-LINE at 800-962-3555.